Blood cancers are no longer classified by appearance alone. Over the past two decades, molecular diagnostics has fundamentally changed how we diagnose, classify, and treat hematologic malignancies. Identifying the specific genetic mutations driving a patient's cancer is now essential for accurate diagnosis and optimal treatment.
Molecular testing refers to laboratory techniques that analyze DNA, RNA, or proteins to detect genetic alterations in cancer cells. In blood cancers, these alterations include point mutations, gene fusions, insertions, deletions, and chromosomal rearrangements. Each type of alteration can influence how the cancer behaves and how it responds to treatment.
Polymerase Chain Reaction (PCR) is one of the most widely used molecular techniques. It amplifies specific DNA sequences to detect known mutations with high sensitivity. In blood cancers, PCR is commonly used to detect BCR-ABL1 fusion in Chronic Myeloid Leukemia (CML), JAK2 V617F mutation in myeloproliferative neoplasms, and FLT3 mutations in AML.
Fluorescence In Situ Hybridization (FISH) uses fluorescent probes to detect specific chromosomal abnormalities directly in cells. It is invaluable for identifying translocations like t(15;17) in Acute Promyelocytic Leukemia, deletions like del(17p) in Chronic Lymphocytic Leukemia, and rearrangements that guide treatment decisions.
Next-Generation Sequencing (NGS) has expanded our ability to test for multiple mutations simultaneously. A single NGS panel can screen for dozens of cancer-related genes, providing a comprehensive molecular profile. This is particularly valuable in AML, where the combination of mutations (e.g., NPM1 with or without FLT3) determines risk category and treatment approach.
The clinical impact of molecular testing is direct: it determines whether a patient with CML receives imatinib, whether an AML patient is classified as favorable or adverse risk, and whether targeted therapies like FLT3 inhibitors or IDH inhibitors are appropriate. Without molecular testing, these decisions would be made with incomplete information.
For patients, the key takeaway is this — if you have been diagnosed with a blood cancer, ask your doctor about molecular testing. Understanding your cancer's genetic profile is not optional; it is a critical part of modern diagnosis and treatment planning.